![Ibodutant Ibodutant](https://upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Ibodutant_structure.svg/400px-Ibodutant_structure.svg.png)
Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.
Owlapps.net - since 2012 - Les chouettes applications du hibou